Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells 7,000 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the sale, the executive vice president now directly owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. The trade was a 5.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Rong Zhou also recently made the following trade(s):

• On Tuesday, November 12th, Rong Zhou sold 6,893 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $48.88, for a total transaction of $336,929.84.

Amphastar Pharmaceuticals Stock Down 3.4 %

AMPH opened at $39.45 on Thursday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The firm has a market capitalization of $1.90 billion, a P/E ratio of 13.15, a PEG ratio of 0.87 and a beta of 0.78. The company’s 50-day moving average is $46.91 and its 200 day moving average is $44.63. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61.

Analysts Set New Price Targets

A number of research firms recently weighed in on AMPH. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price on the stock. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $60.33.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently modified their holdings of the company. GAMMA Investing LLC increased its position in shares of Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after acquiring an additional 273 shares during the last quarter. Innealta Capital LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at $55,000. Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the period. Blue Trust Inc. raised its stake in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. purchased a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth about $78,000. Institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.